Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
spinal muscular atrophy
Fierce Pharma
Novo’s Catalent plant ditched in FDA refiling of SMA drug
A recent FDA inspection of Novo's troubled Catalent site in Indiana has been classified as “Official Action Indicated.”
Angus Liu
Aug 10, 2026 10:06am
Biogen to take Spinraza follow-up into registrational studies
Jun 25, 2025 8:04am
Scholar Rock's SMA drug helps Zepbound patients retain muscle
Jun 18, 2025 9:10am
Biohaven fails phase 3 SMA test but plans talks with FDA
Nov 25, 2024 9:56am
Phase 3 Scholar Rock trial hits SMA goal, sending stock up 327%
Oct 7, 2024 8:45am
Roche, Abu Dhabi partner to study rare spinal disease
May 23, 2024 5:30am
